What is NDC 51662-1477?

51662-1477 is the product NDC for Enalaprilat, Enalaprilat 1.25 mg/mL injection, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 1 package NDC, shown above in 10- and 11-digit form.

HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Enalaprilat?

4 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Enalaprilat NDC 51662-1477 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1477Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1477Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1477-1	5166214770151662147701	1 mL in 1 VIAL (51662-1477-1)Marketed from Feb 1, 2020

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Enalaprilat
Generic name (nonproprietary): enalaprilat
Active ingredients: Enalaprilat — 1.25 mg/mL
Dosage form: Injection
Route: Intravenous
Labeler: HF Acquisition Co LLC, DBA HealthFirstNDC labeler code 51662
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078687
Marketing start: Feb 1, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)Decreased Blood Pressure (Physiologic effect)
Identifiers: Product ID 51662-1477_12044a95-d04f-2681-e063-6394a90af8ccSPL ID 12044a95-d04f-2681-e063-6394a90af8ccSPL set ID 9d88f915-13dd-5463-e053-2a95a90a09bfRxCUI 1729200UNII GV0O7ES0R3
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451662147701 followed by a unit qualifier and the quantity

Package 51662-1477-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 22, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS & USAGE Enalaprilat injection, USP is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection, USP has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, USP, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collage…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51662-1477

What is NDC 51662-1477?: 51662-1477 is the product NDC for Enalaprilat, Enalaprilat 1.25 mg/mL injection, listed with the FDA by HF Acquisition Co LLC, DBA HealthFirst. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Enalaprilat.
What is the active ingredient?: Enalaprilat.
Who is the labeler?: HF Acquisition Co LLC, DBA HealthFirst, NDC labeler code 51662. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Enalaprilat?: 4 other product NDCs are listed under this name. See all Enalaprilat NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Enalaprilat NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Enalaprilat	Enalaprilat 1.25 mg/mL	InjectionIntravenous	Dr. Reddys Laboratories Inc	43598-078	43598-0078-58
Enalaprilat	Enalaprilat 2.5 mg/2mL	InjectionIntravenous	Dr. Reddys Laboratories Inc	43598-169	43598-0169-58
Enalaprilat	Enalaprilat dihydrate 2.5 mg/2mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9786	00143-9786-10
Enalaprilat	Enalaprilat dihydrate 1.25 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9787	00143-9787-10

Other NDCs under ANDA 078687

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078687
Product	Strength	Form · route	Labeler	Product NDC
Enalaprilat	Enalaprilat dihydrate 2.5 mg/2mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9786
Enalaprilat	Enalaprilat dihydrate 1.25 mg/mL	InjectionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9787